MedTrace Logo

Neutrophil Gelatinase Associated Liocalin in Predicting AKI in Coronary Artery Disease

NCT03266367 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2017-09-05

No results posted yet for this study

Summary

The aim of this work is to assess the clinical significance of serum levels of neutrophil gelatinase-associated lipocalin (NGAL) to predict AKI in patients exposed to PCI.

Conditions

Interventions

DIAGNOSTIC_TEST

Neutrophil gelatinase-associated lipocalin (NAGL)

Serum level of Neutrophil gelatinase-associated lipocalin (NAGL) using the enzyme linked immunosorbent assay kits (ELISA)

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-15
Primary Completion
2018-12-01
Completion
2019-09-15

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03266367 on ClinicalTrials.gov